TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients with sarcopenia diagnosed using AWGS criteria consist of low muscle mass: using the BIA examination tool where men: \<7.0kg/m2, women: \<5.7kg/m2 plus low muscle strength using a handgrip dynamometer, men: \<28kg , female : \<18kg or low physical performance using the 6 meter walk test; \<1 meter/second.~Exclusion Criteria:~* Chronic liver disease (cirrhosis of the liver) or severe liver dysfunction or increased SGPT\> 3 times the upper limit of normal value~* Impaired kidney function with a glomerular filtration rate \<30 ml/minute without hemodialysis~* Acute phase of illness (eg infection, acute arthritis, acute stroke, trauma)~* Malignancy~* Depression according to the geriatric depression scale (Geriatric Depression Scale score\> 10)~* History of hypersensitivity to Ophiocephalus striatus~* Refuse to participate in research

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Control group get placebo 2x5 grams a day for 14 days
- Ophiochepalus striatus extract (Type: EXPERIMENTAL): Intervention group get Ophiochepalus striatus extract 2x5 grams a day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Floseal Treatment for Posterior Epistaxis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age greater than 18 years of age~* posterior epistaxis~Exclusion Criteria:~* patients with anterior epistaxis~* known sensitivity to any of the materials of Floseal or the topical medications administered as part of the evaluation and treatment of epistaxis (lidocaine, xylometazoline hydrochloride)~* pregnant or breast feeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Floseal (Type: EXPERIMENTAL): Received 1 syringe of Floseal for treatment of posterior epistaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients in good health as confirmed by medical history~* not pregnant as demonstrated by negative urine pregnancy test~* completed their last term pregnancy at least 42 days prior to Screening and at least one normal menstrual period since last pregnancy~* not lactating~* post-menarcheal and pre-menopausal~Exclusion Criteria:~* History or presence of disorders commonly accepted as contraindications to steroid hormonal therapy including but not limited to the following - active or history of deep vein thrombophlebitis or thromboembolytic disorders or hypercoagulation disorders, cerebral vascular or coronary artery disease, uncontrolled hypertension, or migraines with focal aura, benign or malignant liver tumor which developed during the use of oral contraceptives or estrogen-containing products~* treatment with continuous oral contraception within three months of study~* previous use of contraceptive patch including norelgestromin/ethinyl estradiol~* patients who are amenorrheic (abnormal suppression or absence of menstruation)~* recent history of alcohol or substance abuse~* skin conditions resulting in oily, irritated or damaged skin at potential sites of application

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 001 (Type: EXPERIMENTAL): norelgestromin/ethinyl estradiol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* documented HIV infection~* stable Protease Inhibitor containing HAART regimen for at least 12 months~* impaired glucose tolerance~* elevated insulin levels (above 20 mIU/l)~Exclusion Criteria:~* patients already taking oral hypoglycaemic treatment or insulin~* heart failure NYHA I-IV~* liver disease or kidney disease~* elevated AST or ALT above 2 times upper normal range~* elevated creatinine (above 150 mmol/l)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No clinically important abnormal physical findings.~* No clinically significant laboratory abnormalities.~* Normal (or abnormal but not clinically significant) ECG measurements.~* Body mass index between 18.0 and 32.0 kg/m2.~* Normal (or abnormal but not clinically significant) blood pressure and pulse rate measurements. methylxanthine-containing beverages or food~* Non-smoker~Exclusion Criteria:~* Received any investigational drug within 8 weeks before administration of the first dose of the study drug~* Female who is pregnant, has a positive pregnancy test, or is breastfeeding.~* Positive test result for amphetamines, barbiturates, benzodiazepines, cocaine metabolites, opiates, cannabinoids, methylenedioxymethamphetamine, cotinine, or alcohol in urine at Screening or Day -1.~* Positive screening test for hepatitis B surface antigen, hepatitis C, and/or human immunodeficiency virus antibodies.~* Any surgical or medical condition that, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism, or excretion of the drug.~* Used any medication (prescription or over-the-counter, including health supplements and herbal remedies, with the exception of acetaminophen, as defined in exclusion number 8) within 2 weeks (4 weeks for drugs or substances known to inhibit or induce CYP enzymes and/or P-gp including St. John's wort \[Hypericum perforatum\]) or 5 half-lives (whichever is longer) before the first dose of study drug.~* Used an oral or IV antibiotic within 4 weeks of administration of the first dose of the study drug.~* Routinely or chronically used more than 2 g of acetaminophen daily.~* Performed strenuous activity, sunbathing, and/or contact sports within 96 hours (4 days) before entry into the clinical study site on Day -1, and for the duration of the study.~* Donated or lost greater than 400 mL of blood in the 30 days before administration of the first dose of the study drug.~* History of clinically significant GI disease, or gastroenteritis (vomiting or diarrhea) or any history of GI bleeding (excluding bleeding from hemorrhoids)~* History of any significant drug allergy~* History of any drug or alcohol abuse in the past 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Midazolam/Delafloxacin (Type: EXPERIMENTAL): Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female aged 20 years or more~* History of reflux esophagitis~* Ongoing (until date of Visit 1) treatment with rabeprazole 10 mg, given once daily, for at least 4 weeks.The subject must take rabeprazole at least 4 days a week in the past 7 days prior to Visit 1.~* Persisting symptoms of heartburn experienced at least 2 days during the past 7 days prior to Visit 1.~Exclusion Criteria:~* Use of other PPIs and/or H2RA during rabeprazole treatment~* History or having other gastrointestinal diseases~* History of upper gastrointestinal surgery~* Initiation of medications that can affect digestive functions within 4 weeks before study treatment~* Inability to complete questionnaires

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- esomeprazole 20 mg (Type: OTHER): esomeprazole 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be considered for this study if they suffer from classical or common migraine for at least 3 years.~* Candidates will recruited from the clinical case load of Dr. Zahid Bajwa and the headache and pain management center at BIDMC.~* Only patients older than 18 years of age,~* Able to communicate clearly in English,~* Able to give an informed consent will be considered as candidates.~* No limitation of gender or race is justified and thus, it is open to all patients fulfilling criteria for migraine type headache.~* Patients will be able to withdraw from the study at any time.~* They will be included in the study if they meet the criteria for migraine with or without aura (Headache-classification-committee-of-the-International-Headache-Society 1988), if they had \>4 migraine attacks each month for the previous year.~Exclusion Criteria:~* Exclusion criteria will include cardiovascular or cerebrovascular disorders,~* Cardiac risk factors and liver disease,~* Uncontrolled hypertension,~* Peripheral and central nervous system disorders that affect sensory functions (such as sensory neuropathies and chronic pain),~* The use of opiates or other analgesic drugs for any reason, and the use of other prophylactic anti-migraine drugs.~* Any patient with active hepatitis or elevated liver enzymes (based on their BIDMC medical record) will be excluded as well.~* Employees who are under the direct supervision of the investigators will not participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Maxalt administration at onset of migraine
- 2 (Type: PLACEBO_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 or above~* Congestive Heart Failure with symptoms for more than 4 weeks before starting study~* Provision of informed consent~Exclusion Criteria:~* Current low blood pressure with symptoms~* Liver disease considered significant by the study doctor~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children must be healthy to participate~Exclusion Criteria:~* Immunosuppressive (including HIV) conditions, allergic diseases, neurological disorders, known anaphylactic reaction to MMR vaccine, and fever (axillary temperature ³ 37.5°C at the time of vaccination) are excluding factors.~* Children must have received one dose (but not more) of MMR at least 6 weeks before entering the study.~* They must not receive or have received other non-registered drug or vaccine within 30 days prior to study start, or immunosuppressants for more than 14 days.~* Immunoglobulins or any blood products are prohibited during the 6 months before and during the study, as well as vaccine other than that foreseen by the protocol, 30 days before until 56 days after vaccination.~* Children must not have been vaccinated against varicella.~* They must not have had measles, mumps, rubella or varicella, or have been exposed to those diseases within 30 days prior to study start.~* New-born infants (\< 5 weeks of age), pregnant women without previous exposure to chickenpox, and immunodeficient persons cannot live in the same household as the vaccinated child.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* T-ALL; T-NHL~* age \>= 18 years~* cytological treatment failure / relapse~* molecular treatment failure / relapse~* no promising therapy alternatives with approved medication available~* no CNS-manifestation, requiring intrathecal therapy or CNS-radiation~* no convulsive disease or neurotoxicity \> grade III in patients history~* written informed consent~* no cytostatic therapy in the last 10 days~* no pregnancy or breastfeeding~* effective contraception~* recovery of toxicities of previous chemotherapy - except leukemia- related changes like bone marrow suppression or pathological transaminases in liver manifestation~Exclusion Criteria:~* Severe psychiatric illness~* uncontrolled or severe cardiac disease or infection~* active secondary neoplasms - except skin cancer (no melanoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Nelarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project to Improve Symptoms and Mood in People With Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spinal cord injury (ASIA A-D)~* At least one month post injury~* Meets DSM IV criteria for major depression or dysthymia on the SCID~* At least moderately severe depression (PHQ-9 score \>= 10)~* Within reasonable travel distance to one of the study sites~Exclusion Criteria:~* Current DSM IV alcohol or drug dependence~* History of bipolar disorder or psychosis~* History of \>= 2 suicide attempts or suicide attempt with 5 years~* Current suicidal intent or plan~* Medical contraindications~* Non-English speaker~* Clinically significant cognitive/language impairment~* History of allergic reaction to venlafaxine XR or use of MAO-I with 2 weeks~* Current use of antidepressant medications (will not exclude if on low dose of a tricyclic antidepressant or trazodone for pain, sleep, or bladder), psychotherapy for depression, or electroconvulsive therapy~* Pregnant or lactating women or women of childbearing potential who are not willing to use a reliable form of contraception~* Unstable medical condition, as determined by physical examination, CBC w/ platelets (including hematocrit, hemoglobin, WBC, differential), serum chemistry panel (serum sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose), liver transaminases (AST, ALT), thyroid stimulating hormone (TSH), urinalysis, supine diastolic blood pressure (SDBP) \> 90 mm Hg, or near terminal illness (primary care physician estimates that patient has \< 1 year to live)~* Anticipated major surgical procedures within the 12 weeks of randomization~* Use of an investigational drug within 30 days~* Use of psychoactive medications, including corticosteroids and anticonvulsants, that have not been at a stable dose for at least 2 weeks~* Use of anxiolytic, sedative-hypnotic, or other psychotropic drug or substance (including St. John's Wort) within 7 days of start of double-blind treatment. If the patient is taking a sedative deemed necessary for sleep induction or spasticity, the dosage must have been stable for at least 2 weeks. Use of anticholinergic, low-dose tricyclic antidepressant, GABAergic or adrenergic medications for spasticity are permitted if at a stable dose for at least 2 weeks.~* Refusal to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
- venlafaxine XR (Type: EXPERIMENTAL): venlafaxine XR 37.5 - 300 mg/day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older with a diagnosis of chronic intermediate uveitis in at least one eye~Exclusion Criteria:~* Uncontrolled systemic disease~* Any active ocular infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Dexamethasone 350 µg
- 2 (Type: ACTIVE_COMPARATOR): Dexamethasone 700 µg
- 3 (Type: SHAM_COMPARATOR): Sham

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Barrett's without dysplasia~* Barrett's with dysplasia~* Esophageal Adenocarcinoma~Exclusion Criteria:~* Subjects unfit for standard upper endoscopy~* Subjects currently receiving chemo or radiation treatment~* Subject currently receiving PDT or ablation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proflavine Hemisulfate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* colonoscopy indicated~Exclusion Criteria:~* congestive heart failure~* ascites~* renal failure~* hyponatremia~* previous intestinal surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Split Dose (Type: EXPERIMENTAL): Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
- Traditional Dose (Type: ACTIVE_COMPARATOR): Both doses of Pico-Salax taken the evening prior to colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete